Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73

IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo

(2014) Avinashnarayan Venkatanarayan et al.   NATURE

Erratum: Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes

(2013) Karen Pillay et al.   Biomed Research International

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

(2011) Colleen A. Brady et al.   CELL

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

(2011) Yongxing Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Stage-specific sensitivity to p53 restoration during lung cancer progression

(2010) David M. Feldser et al.   NATURE

TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs

(2010) Xiaohua Su et al.   NATURE

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

(2010) S. Suzuki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pramlintide in the Treatment of Diabetes Mellitus

(2008) Steve Edelman et al.   BIODRUGS

TAp73 knockout shows genomic instability with infertility and tumor suppressor functions

(2008) R. Tomasini et al.   GENES & DEVELOPMENT